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Abstract 
Background: The spectrum of central nervous system autoimmune disorders has 
recently expanded with the discovery of disorders associated with antibodies directed 
against the neuronal membrane surface. Although many of these disorders have an 
underlying malignancy and present with signs of dysfunction of the limbic system 
(paraneoplastic limbic encephalitis, PLE), a high proportion of cases is non-
paraneoplastic. They may occur with milder symptoms, and present no abnormalities in 
the exams usually used in the investigation of PLE. A striking number of cases may be 
misdiagnosed as primary psychiatric or other neurological disorders. 
Objective:  Review the current knowledge on this topic, and provide physicians with an 
updated text on the neuropsychiatric presentation, diagnostic approach and current 
management of autoimmune encephalopathies. 
Methods: We searched Pubmed for articles in English until December 2013, using the 
terms: "Autoimmune limbic encephalitis"; “Limbic encephalitis”; “Psychiatry”; “Psychotic 
Disorders”; “Anti-N-Methyl-D-Aspartate Receptor Encephalitis”; "Gamma-aminobutyric-
acid receptor”;  “Leucine-rich-glioma-inactivated 1”; "Voltage-gated-potassium channel”; 
"α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic-acid receptor”; “Ri”; “Ma2”; and “Hu”. 
We restricted the search to human studies, and selected articles for further analysis. The 
Article reference lists were also reviewed and relevant articles retrieved for consultation. 
Results: 109 articles have been reviewed, and data summarized. The authors propose a 
diagnostic flowchart. 
Conclusions: Autoimmune encephalitis is not a rare disorder, often has a psychiatric 
presentation, and should be considered whenever a non-psychiatric etiology is 
considered. Diagnosis is often challenging, but certain clinical features should rise 
suspicion about an underlying autoimmune or paraneoplastic disorder, thus guiding the 
physician to structured investigations, including tumor screening, and adequate 
therapeutic interventions, namely immunotherapy. 
 
GLOSSARY 
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ANNA-1: anti-
neuronal nuclear antibodies 1; ANNA-2: anti-neuronal nuclear antibodies 2; ANNA-3: anti-
neuronal nuclear antibodies 3; Caspr2: contactin-associated-protein relates 2; 
CV2/CRMP5: crossveinless-2/collapsing response mediated protein 5; FDG-PET: 
fluorodeoxyglucose-positron emission tomography; FLAIR: fluid-attenuated inversion 
recovery; GABABR: gamma-aminobutyric acid receptor B; GAD: glutamic acid 
decarboxylase ; LE: limbic encephalitis; LGI-1: leucine-rich glioma inactivated 1; NMDAR: 
N-methyl-D-aspartate receptor; VGKC: voltage-gated potassium channel. 
 
INTRODUCTION 
The association between antibodies and encephalopathies has been known for several 
decades, since paraneoplastic limbic encephalitis (PLE) was first described, back in the 
1960’s. Since then, the clinical spectrum of central nervous system autoimmune disorders 
has expanded astonishingly. In the past decade, several new antibodies against proteins 
and receptors involved in synaptic transmission and neuronal plasticity have been 
discovered in patients presenting with encephalitis. When compared to PLE, they differ in 
their pathophysiology, cancer association, and clinical response, since not all cases are 
paraneoplastic, they occur frequently in young individuals and children, and can show an 
impressive response to immunotherapy.(1-6) 
Furthermore, while PLE is uncommon, recent data suggests a much higher prevalence of 
non-paraneoplastic autoimmune encephalitis (AE) than previously imagined. Autoimmune 
etiology was reported in 7% of patients in a sample of 203 individuals with encephalitis. 
This percentage might even be higher since in cases associated with unknown causes, 
only anti-VGKC and NMDAR antibodies were searched for. (7) Also, in the last few years, 
several case reports describing milder or atypical presentations have been published. 
These cases of encephalitis can present predominantly or solely with psychiatric 
symptoms, frequently mimicking schizophreniform or mood disorders. (8-30)  Hence, this 
diagnostic entity can present as a clinical challenge to any physician, especially 
neurologists and psychiatrists, whom the majority of patients seek for help first.  
This paper aims to review the current knowledge on this topic, and to clarify physicians 
about the neuropsychiatric presentation of the most common autoimmune 
encephalopathies, their diagnostic approach and current management. 
 
 
CLINICAL PRESENTATION, WITH EMPHASIS ON NEUROPSYCHIATRIC FEATURES 
Antinuclear/cytoplasmatic autoimmune encephalitis 
Anti-nuclear antibodies usually occur in PLE. As the name suggests, symptoms related to 
limbic system involvement predominate, as individuals present with the classic triad of 
memory impairment, temporal lobe seizures and psychiatric symptoms. It occurs 
predominantly in the elderly and, like most paraneoplastic syndromes, a higher incidence 
is noted in women. (31)  
Seizures can be subtle, and even follow an unrecognized course. Cognitive impairment, 
such as confusion or short-term memory dysfunction, occurs within days to weeks, and 
progression to dementia may be noted over time. Overall, depression, psychosis, and 
behavioral changes are the most usual psychiatric spectrum manifestations, sometimes 
accompanied by delusions and hallucinations. Patients can also experience sleep 
disturbances and obsessive-compulsive behavior (OCB). (31, 32) 
Data suggest that classical onconeuronal antibodies have no pathological role, and that 
central nervous system (CNS) damage is mediated by T cells. Nevertheless, these 
antibodies underlie different tumor associations, disorder-predominant neuropsychiatric 
features, and response to treatment. (5, 33) 
PLE associated with anti-Hu, also called anti-neuronal nuclear antibodies 1 (ANNA-1), 
occurs in older patients usually with a long history of smoking, as 74% of patients with 
underlying malignancy have small cell lung carcinoma (SCLC). More frequently than 
limbic encephalitis (LE), individuals present with sensory neuropathy (54%), cerebellar 
ataxia (10%), or multisystem disease (11%). More commonly they have depression or 
hallucinations, but confusion, sleep disturbances, agitation, and anxiety can occur. These 
symptoms respond poorly to antipsychotics and sedatives, and are followed by the onset 
of seizures, ataxia, and depressed alertness. (34)  
On the contrary, anti-Ma2 is more often seen in younger men, and there is a strong 
association with testicular cancer. Besides LE, they can also develop diencephalic or 
brainstem encephalitis, or a disorder with mixed features. Individuals usually display 
severe short-term memory deficits, gait disturbances, and hypokinesia. Signs of 
hypothalamic dysfunction (i.e., diurnal hypersomnia, cataplexy, hyperphagia, hormonal 
deficits, hyperthermia, weight gain, or sexual dysfunction) occur in up to one third of 
patients. Signs of brainstem dysfunction include cranial neuropathy, nuclear or 
supranuclear ophtalmoparesis, dysarthria, dysphagia, and parkinsonism. Anxiety, OCB, 
and personality changes are the most frequently reported psychopathological 
manifestations. Contrarily to anti-Hu, mood disorders and hallucinations are rare. Anti-
Ma1 antibodies can also be present and are associated with female gender, older 
patients, cerebellar dysfunction and malignancies other than testicular, thus predicting 
poorer prognosis. (35) 
Another common antibody in PLE is anti-crossveinless-2/collapsing response mediated 
protein 5 (anti-CV2/CRMP5). It has a strong association with thymoma and SCLC (in this 
particular case, it may co-exist with anti-Hu), but can also occur with other malignancies, 
such as uterine sarcoma. It associates with a wide range of neurological and psychiatric 
symptoms, being subacute dementia and peripheral neuropathy the most common. 
Ocular abnormalities (optic neuritis, posterior uveitis), olfactory or taste loss are more 
frequent than in other forms of PLE, and the presence of chorea, particularly facial, is 
highly suggestive. Patients may also display personality changes, depression, confusion, 
psychosis, manic mood, OCB, memory deficits, spatial and temporal disorientation. (36-
38) 
Anti-Ri antibody, also called ANNA-2, is a rare oncoantibody associated with breast, lung, 
or cervical cancer. It is more frequent in the female gender and has been associated with 
several neurological paraneoplastic syndromes, most frequently brainstem symptoms, but 
cerebellar syndrome, peripheral neuropathy, cranial neuropathy, Lambert-Eaton 
myasthenic syndrome (LEMS), and limbic encephalitis can also coexist. Patients can 
present with subacute behavioral and neuropsychiatric changes, (39, 40) although gait 
instability is the commonest symptom at presentation. Most individuals develop multifocal 
neurological impairment, including ataxia, opsoclonus, myoclonus, jaw-opening dystonia, 
visual blurring, laryngospasm, sphincter incontinence, cranial nerve impairment, 
peripheral neuropathy, or myelopathy. Neurological impairment can be severe, and 60% 
of the patients will require the use of a wheelchair.  Contrarily to ANNA-1, gastrointestinal 
motility disorders are not common. Most patients show concomitant antibodies in serum 
(Hu, CRMP5, GAD65, but also thyroid peroxidase or thyroglobulin), suggesting 
predisposition to autoimmunity, and the majority will respond to immunotherapy. (40-42) 
Other oncoantibodies associated with paraneoplastic neurological syndromes include anti-
amphyphisin, anti-Yo/anti-Purkinje cell 1 (PCA-1), and, less commonly, anti-neuronal 
nuclear antibodies 3 (ANNA-3), anti-Purkinje cell 2 (PCA2), anti-Zic4, and anti-mGluR1, 
found in several syndromes, especially paraneoplastic cerebellar degeneration or stiff-
person syndrome (SPS). (33) 
In most patients, PLE will present before cancer is diagnosed, so tumoral screening in the 
presence of onconeuronal antibodies is mandatory. Coexistence with anti-surface 
antibodies, most commonly anti-VGKC, can occur, as does the development of 
onconeural-antibodies-associated LE without an underlying malignancy, although less 
frequenty. (33, 34) 
More recently, anti-Glutamic Acid Decarboxylase (GAD), already associated with diabetes 
mellitus type 1, SPS, cerebellar ataxia, and epilepsy, has been associated with 
nonparaneoplastic LE. These patients are more frequently young adults (median age 23 
years old), with female predominance. Seizures are universal at presentation and 
cognitive impairment or psychiatric disturbances are rare. This disorder usually responds 
to immunotherapy, but to a much less extent than anti-surface disorders, and patients 
rarely become seizure-free. (43) Another recent study also reported the presence of GAD 
antibodies in idiopathic limbic encephalitis in children. All had fever and acute clinical 
deterioration, followed by refractory seizures and a wide spectrum of neuropsychiatric 
disturbances, even after immunomodulatory therapy. (44)   
 
ANTI-NEURONAL SURFACE AUTOIMMUNE ENCEPHALITIS 
Anti-VGKC complex 
These antibodies are associated with a wide range of clinical manifestations such as LE, 
cramp fasciculation syndrome, Isaac’s syndrome, LEMS, or Morvan’s syndrome.  
Previously thought to be a disorder associated with antibodies to the voltage-gated 
potassium channels (VGKC), recent studies revealed that in fact, the targets are the 
associated proteins, rather than the channel itself. (45) Most cases are associated with 
antibodies against leucine-rich glioma inactivated 1 (LGI1) or contactin-associated protein 
relates 2 (Caspr2), but evidence suggest that other still unrecognized antibodies to VGKC-
associated proteins might be involved, explaining such diversity. (46) Although cell-based 
assays can differentiate them, radioimmunoassay (RIA, still considered the diagnostic 
gold-standard exam), cannot, and they are still commonly called VGKC-complex 
antibodies.  
Anti-LGI1 is by far the most common and afflicts middle-aged to older patients. It is almost 
exclusive of patients exhibiting the classic LE clinical presentation triad. Tumor 
association is infrequent, occurring in 11% of the patients. (45) Concerning Caspr2, the 
spectrum of associated disturbances is wider (LE, Morvan’s syndrome, neuromyotonia, 
painful neuropathy) and has a stronger association with cancer, notably thymoma. (47, 
48)  
Signs of autonomic dysfunction such as sialorrhea and hyperhydrosis are common 
features. Hyponatremia, often resistant to treatment, (49) and faciobrachial dystonic 
seizures (FBDS), are other peculiar symptoms. FBDS are almost exclusive of patients 
with anti-LGI1 antibodies and present as frequent, sudden, brief myoclonic-like 
movements, with facial grimacing accompanied by ipsilateral arm posturing, often 
preceding the onset of other symptoms. They are often resistant to antiepileptic drugs but 
show a good response to immunotherapy. Verbal and visual memory deficits may also be 
present. (50) Organ specific autoimmunity is seen in one third of these patients, often with 
a family history of autoimmune disorder. (51, 52) 
Common disturbances include behavioral changes, depression, hallucinations and 
delusions, as well as REM sleep disorders. (52) 
Seizures occur in the majority of patients, usually of the temporal lobe type but the frontal 
lobe can also be involved, without EEG abnormalities even during the seizure, thus can 
be mistaken for psychogenic non-epileptic seizures. (53) 
 
Anti-NMDAR 
This is probably the most common form of autoimmune encephalitis (AE). Since it was 
first reported in 2006, the number of cases dramatically increased, surpassing the 500 
cases, with the California encephalitis project reporting an incidence nearly as high as 
viral encephalitis. (54) 
It is more common in young females (median age 21 years, but age range between 8 
months and 85 years), and nearly half are paraneoplastic. Ovarian teratoma is by far the 
most frequent malignancy, particularly between 12 and 45 years old, especially in females 
of African or Asian descent. SCLC, neuroblastoma, breast carcinoma, thymoma, testicular 
cancer, and non-gonadal teratomas may also underlie this disorder, especially in older 
patients. (55-57)  
Unlike most AEs, symptoms are not mainly limited to the limbic system. Clinical 
manifestations can be subdivided into eight categories: behavior, cognition, memory 
deficits, seizures, movement disorders, impairment of alertness, autonomic dysfunction, 
and central hypoventilation. Although initially monosymptomatic, the majority of patients 
will exhibit symptoms in at least 4 categories within 4 weeks after presentation, with 
monosymptomatic disease occurring in only 5% of individuals. (56) 
The initial clinical presentation differs among age groups: while adults tend to manifest 
behavioral changes, movement disorders and seizures are more common in children, 
although psychopathological manifestations can also dominate the clinical picture (29, 58-
61), as well as developmental regression. (13) In older adults (> 45 years) predominant 
symptoms also diverge, as they are more prone to exhibit behavioral changes, and 
cognitive impairment, and less commonly movement disorders, decreased level of 
consciousness, or prodromal symptoms.  (57) In the extremes of age, no gender 
preference is observed, with tumors or need for ventilatory support being less frequent.  
In young adults, this disorder evolves according to a pattern that often starts with a flu-like 
prodromal phase, characterized by fever, headache, gastrointestinal, or upper respiratory 
symptoms. Subsequently psychiatric symptoms arise, isolated or along with cognitive 
decline and/or seizures. Two to three weeks after presentation, movement disorders and 
autonomic instability surface, followed by impaired consciousness and central respiratory 
dysfunction, often warranting to admission to the intensive care unit, with the need of 
ventilatory support. (62) 
Psychiatric manifestations include anxiety, agitation, mania, depression, bizarre behavior, 
delusional and/or paranoid thoughts, and visual or auditory hallucinations, frequently 
refractory to antipsychotic therapy. In a retrospective study on 100 patients diagnosed 
with anti-NMDAR encephalitis, all presented psychiatric symptoms, and 77% were first 
seen by a psychiatrist. (63) Patients are often misdiagnosed with primary psychiatric 
disorder, usually psychotic illness. Data from 571 patients showed that purely psychiatric 
presentation could occur in up to 4%, and in up to 28% in relapsing disease. (62) More 
commonly these individuals have delusional thinking (74%), half will show aggressive 
behavior, and hallucinations is noted in 43%. Mood disorders occur in 70%, more often 
mania. Emotional lability or impulsivity is also common. (64) 
Movement disorders include jaw-opening dystonia, facial grimancing, athetosis/dystonia 
or orolingual-facial dyskinetic movements, opisthotonic postures, and limbs or trunk 
choreoathetosis. Autonomic dysfunction manifests as tachycardia/bradycardia, 
hyperhidrosis, persistent pyrexia, central hypoventilation, blood pressure fluctuation, 
hypersalivation, intestinal pseudoobstruction, and cardiac arrest. (55, 62) 
Relapses occur in 24% of patients, with higher incidence in those who did not received 
immunotherapy(65), and in nonparaneoplastic cases (56), sometimes several years after 
discharge, (66) justifying long follow-up periods and probably the use of long-term 
immunossupression.  
 
Anti-AMPAR  
Almost all patients are older females (median age 60 years), with relapsing LE. Most 
cases are paraneoplastic, usually coexisting with breast cancer, lung carcinoma, or 
thymus cancer. (67) Although only a few cases have been reported, the clinical 
presentation is variable, since more insidious disease, with progressive memory loss and 
behavioral changes suggesting dementia has been described, (68) as well as fulminant 
disease with acute confusion, hypersomnia, visual hallucinations, and combativeness 
accompanied by severe memory loss and brain atrophy. (69) 
Psychopathological manifestations in these patients include confusion, sleep 
disturbances, aggressiveness, hallucinations, confabulation, lethargy, combativeness and 
perseveration. Other reported features are seizures, nystagmus, decreased level of 
consciousness, and gait unsteadiness. (67) 
These data are based in a small number of reported patients and further studies are 
necessary to clarify the clinical presentation, progression and prognosis. 
 
Other anti-neuropil antibodies 
Anti-GABAB AE is an apparently rare and recently described anti-surface LE. Almost all 
cases are older men (median age 60 years). It is thought to be the most frequent antibody 
in ALE associated with SCLC previously considered “seronegative”. (70) Idiopathic forms 
have also been reported, more commonly in younger patients (median age 30 years old). 
Seizures, often unresponsive to treatment, are the predominant symptom at presentation, 
along with confusion, disorientation, striking memory impairment and behavioral changes, 
suggesting LE. Psychiatric symptoms reported include psychosis, paranoia, confabulation, 
delusions, sleep abnormalities, and visual/gustatory hallucinations.  
These antibodies can coexist with anti-Hu, SOX-1, TPO, anti-VGKC complex and anti-
GAD antibodies, the latter more frequently in paraneoplastic cases. Besides SCLC, 
neuroendocrine lung cancer and thymus carcinoma can also occur. The outcome is worse 
as compared to other disorders with anti-neuronal surface antibodies, since response to 
treatment is frequent, but full recovery is rare and death due to the underlying malignancy 
is common. (71, 72) 
More recently, basal ganglia encephalitis, associated with antibodies against Dopamine 
receptor 2 (DR2) has been described in children previously diagnosed with encephalitis 
lethargica, similar to what has been observed with anti-NMDAR AE.(73) In these patients 
there is a predominance of movement disorders but psychiatric symptoms are also quite 
common, as do sleep disturbances. None were paraneoplastic, there was no gender or 
ethnic preference, and in most there was a history of recent infection or immunization. 
(74) 
 
DIAGNOSTIC APPROACH 
Definitive diagnosis of LE will include typical clinical presentation, and either 
neuroradiological evidence of limbic system involvement, CSF inflammatory changes, 
detection of antibodies or response to immunosuppressive therapy. (75) Furthermore, for 
the disorder to be considered paraneoplastic, other etiologies of limbic dysfunction should 
be judiciously excluded, and cancer should be demonstrated within 5 years of the 
diagnosis, in association with a well-characterized paraneoplastic antibody. (33)  
However, since some of these new disorders show atypical presentation and normal 
neuroradiological findings, it has been proposed that the definitive diagnosis of anti-
surface mediated CNS disorders could be made by the existence of antibodies in serum 
or CSF, and clinical improvement under immunotherapy. Furthermore, diagnosis of an 
autoimmune disorder can be made if patients test positive for anti-surface antibodies, or if 
there is history of autoimmune disorder or prodromal syndrome, and improvement with 
immunotherapy. The same authors consider that the diagnosis of  authors consider that 
with antibodies mediated syndrome can be made even in the absence of anti-neuronal 
antibodies, provided that clinical presentation is compatible and patients present neuronal 
markers of autoimmunity, or prodromal syndrome, or history of an autoimmune disorder, 
or response to immunotherapy. (75) 
When compared to the viral etiology, seizures, movement disorders, language 
dysfunction, and psychiatric manifestations are commoner in AE, while autonomic 
dysfunction is very suggestive of the latter. (54) In the paraneoplastic syndrome 
associated with anti-CV2/CRMP5, due to the coexistence of chorea and psychiatric 
symptoms, Huntington’s and Wilson‘s disease should be excluded. Another common 
presentation can be acute dementia, (76) and other causes of rapidly progressing 
dementia should also be excluded. Some possible differential diagnoses are listed In 
Table 3.  As previously noted, most of them, particularly the early stage of NMDAR AE, 
can mimic primary psychiatric disease, most frequently schizophreniform illness with 
acute disorganized behavior or catatonia. Certain features should raise the suspicion of 
autoimmune encephalitis, particularly in a first psychotic episode. [Table 4] 
Neurological examination is often unremarkable, besides any cognitive or behavioral 
features. Full blood count, evaluation of renal, hepatic and thyroid function, prolactin, 
cortisol, serum protein electrophoresis, cobalamin and folic acid level, serum ions, 
serological screen for autoimmune disorders, toxicological tests (when appropriate) and 
viral screening tests should be performed.  
Afterwards, the standard clinical investigation includes brain MRI, EEG, CSF analysis, 
autoantibody screening and eventually positron emission tomography (PET). The findings 
may vary among the different subtypes of AE, as well as their prevalence (table 5).  The 
typical magnetic resonance imaging (MRI) of  PLE shows increased temporomesial signal 
intensity on T2/FLAIR weighted sequences, with swollen anterior structures, unilaterally or 
bilaterally (asymmetry is common). Later, it evolves to hippocampal atrophy, with 
persistent swelling remaining after six months mainly in patients with poor response to 
treatment. (77) Such findings are rarer in anti-neuronal membrane AE. In NMDAR AE 
normal imaging is the rule, and lesions outside the limbic system are commoner. (78, 79) 
The same findings can also be seen, although to a lesser degree, in anti-VGKC complex 
and anti-AMPAR AE. (49, 67) 
Fluorodeoxyglucose-PET (FDG-PET) often detects changes in the brain when other 
imaging tests reveal no abnormalities, including MRI. (6, 28, 79-82) There is correlation 
between the type of antibodies and FGD-PET findings: while classical PLE presents 
mesiotemporal hypermetabolism, accompanied by hypometabolism in the associative 
cortices,(80) anti-surface antibodies show more frequently normal scans or findings 
elsewhere in the brain. Common locations include cerebellum, thalamus, parietal or 
occipital cortices. (79) In NMDAR, findings have been further divided into two major 
patterns. The first one is more often seen in younger patients, and consists of increased 
metabolism in the temporal and orbitofrontal cortex, with hypometabolism in the occipital 
cortex and diffuse borderline hypermetabolism in the cerebellum, usually referred to as 
fronto-temporo-occipital gradient. (83) The second pattern is seen in older patients, with 
less striking symptoms and without seizures. In this group, FDG-PET shows diffuse 
decreased metabolism, more striking in the temporal lobes, with normal uptake in 
subcortical structures.(84) It is still not clear whether these findings represent different 
stages of disease evolution.  
EEG abnormalities are almost universal, usually nonspecific, including diffuse or focal 
slowing, rhythmic intermittent frontal or temporal delta activity (FIRDA or TIRDA), or 
temporal epileptiform activity. (85, 86) In anti-NMDAR AE, a specific pattern, called 
“extreme delta brush” (EDB) has been observed in 30% of patients in small series. This 
pattern has not been described in any other disorder, and these patients show more 
frequently a normal MRI, longer hospitalization, and worse prognosis, suggesting that it 
might be a marker of more severe disease. (84, 87) In the pediatric group, EEG findings 
also seem to have prognostic value: while patients with normal physiological background 
activity (PBA), with unilateral or focal abnormalities, presented with milder neurological 
impairment and better outcome, those patients who had more diffuse abnormalities 
without PBA showed more severe neurological symptoms and a poorer outcome. (88)  
CSF analysis often reveals lymphocytic pleocytosis, increased protein concentration or 
presence of oligoclonal bands (OCB). (32) OCB are a highly specific finding of AE (96%), 
particularly of NMDAR or GAD AE, but sensitivity is low (36%). (89) In anti-NMDAR AE, 
over 80% of patients have an abnormal CSF at presentation; progression of findings is 
usually characterided by an early phase with lymphocytic pleocytosis, with or without 
elevated protein levels, followed by the decrease of white blood cells in CSF and the 
appearance of OCB. On the other hand, with anti-VGKC only half of the individuals show 
abnormal CSF screen and even rarely present OCB. (90, 91) 
Antibody titers can be determined in both serum and CSF. Gold-standard test differs 
among the different antibodies, since onconeuronal antigens are linear, and can be 
detected either by immunobloting, ELISA or immunohistochemistry using mammalian 
brain; anti-surface antibodies are directed against conformational epitopes, losing their 
reactivity when the antigen is denatured. So, they require either an adapted 
immunohistochemistry protocol, the use of live neurons, or cell-based assays. (92)  
Contrarily to anti-nuclear antibodies, in anti-neuropil-associated AE, antibody titers often 
correlate with symptomatic improvement (4, 93), but they can also decrease with time, 
even without therapy and irrespectively of clinical outcome (90, 94), their levels fluctuate 
due to immunosupressants (particularly in serum), and they can remain elevated for years 
after recovery. (66, 92, 95) 
Finally, further investigation to exclude an underlying neoplasm should be considered in 
all cases, since the neurological presentation often precedes the diagnosis of cancer. 
Tumor screening should be focused on most commonly associated malignancies. In 
children at least an ultrasound and MRI of the abdomen is advised. (60)  Other advised 
screening tests are listed on table 6. Imaging screening might not be sensible enough to 
detect microtumors, thus repeated exams every 3 to 6 months during 4 years is 
recommended if no malignancy is found in the meantime. (96) In case of relapsing 
disease, the possibility of an undetected or recurrent tumor should be considered.  
 
MANAGEMENT AND FOLLOW-UP 
Once other relevant causes have been ruled out, immunotherapy should be considered in 
all cases. Since most disorders are rare and/or were recently classified, there are no 
robust randomized clinical trials able to provide evidence-based recommendations.. 
Current treatment options are based on case reports and uncontrolled case series. 
Cancer treatment should always be carried out, when applicable, (56, 62) since combined 
treatment typically results in more favorable outcome than immunotherapy alone. (97) 
Treatment includes high-dose corticosteroids (CT), intravenous immunoglobulin (iv-Ig) 
and plasma exchange as first line immunotherapy. Rituximab, azathioprine and 
cyclophosphamide are considered second line therapeutic interventions, thus prescribed 
when individuals fail to respond to first line drugs. Due to the high occurrence of relapsing 
disease, chronic immunossupressant therapy with mycophenolate mofetil or azathioprine 
can also be considered.  
It has been suggested that the response to treatment could be evaluated with the modified 
Rankin Scale (mRS); treatment has been considered successful if the score lowers at 
least one point on mRS. (56) 
Classic anti-nuclear PLE usually follows a monophasic course, even with combined 
treatment, and prognosis is poor, with extremely rare cases of spontaneous recovery 
without treatment. (98) The exception to this rule is anti-Ma2, usually with better 
prognosis, with one third of patients having a complete recovery, and clinical stabilization 
in one fifth. Some features associate with better outcome, including male gender, younger 
age (< 45 years), with complete response to treatment with underlying testicular tumor, 
absence of anti-Ma1 antibodies, and limited involvement of the CNS.  (35) These severity 
hallmarks differ for anti-Hu, with older patients (> 60 years), RMS > 3, involvement of 
more than one area of the CNS, and absence or delayed treatment being considered 
mortality predictors. (31, 34) 
In anti-VGKC-complex AE, immunotherapy has been tried with intravenous 
methylprednisolone 1 gram or 30-50 mg/kg for 5 days, or iv-Ig 0.4 g/kg for 3-5 days, or 5 
to 7 cycles of plasmapheresis (on alternate days). If patients respond to this treatment 
within 6 weeks, then a corticosparing agent can be initiated. If not, or in case of relapsing 
disease, second line therapy should be promptly considered. (51)  In these patients, good 
outcome is correlated with early treatment, and the initial therapy regiment (with CT and 
iv-Ig apparently better than CT alone). (91) In cases of presentation with FBDS, 
immunotherapy should also be administered, since many patients are resistant to 
antiepileptic drugs (AED). Furthermore, evidence suggests than immunotherapy at this 
early stage might prevent the emergence of cognitive impairment. (91, 99) 
In anti-NMDAR AE, the most commonly used strategy is iv-Ig 0.4 g/kg/day for 5 days, plus 
methylprednisolone 1 g/day for 5 days; plasma exchange is postponed for treatment 
failure cases. (100) If no improvement occurs after 4 weeks of first therapy, second line 
drugs should be considered. (56) Once again, early treatment, younger age, no need for 
intensive care, and longer follow up are associated with better prognosis.(56, 94)  
Electroconvulsive therapy (ECT) has been used to treat these patients, with rapid 
improvement of autonomic dysfunction, psychosis, delusions, stupor and catatonia, and it 
might be used as a second line treatment in patients refractory to pharmacological 
therapy. (101) Nevertheless, it is still a controversial procedure, with a wide range of 
reported clinical response. (102) 
Figure 1 summarizes how clinical features can guide antibody screening in cases of 
suspected AE. 
 
CONCLUSION 
It is a fact that autoimmune encephalopathies, particularly those with antibodies directed 
against the cell surface membrane and associated proteins, can present with psychiatric 
symptoms, and many of these individuals seek psychiatric help first. Hence the 
importance of including this disorder in the list of possible differential diagnoses in patients 
presenting with a new-onset or atypical psychotic or mood disturbance, especially if there 
is no history of mental illness, not only in elderly patients but also in young adults and 
children. (103) 
After exclusion of commoner causes, antibody testing should be performed, since no 
clinical symptom or finding is pathognomonic, but some are highly suggestive of a given 
disorder (figure 1). Antibody screening may provide the correct diagnosis, can help direct 
cancer screening, thus avoiding unnecessary costs, and also provides clues regarding 
prognosis and likely response to therapy.  
Some patients may show negative antibody screening on the currently available tests, 
even when clinical presentation is archetypal. (104-107) These patients may also improve 
with immunosuppressant therapy, thus immunotherapy is strongly advised in cases with 
highly suggestive clinical presentation, after viral etiology has been appropriately 
excluded; tumor screening should also be carried out. (108)  Although complete recovery 
in the absence of immunotherapy has been reported, prompt prescription is associated 
with a better prognosis in most instances. Patients who do not receive proper treatment 
usually suffer from slower recovery, longer hospitalization periods, and a higher risk of 
relapsing disease. (65)  
The startling number of cases of autoimmune encephalitis described in the last decade 
suggests that this is not a rare disorder and it is likely underdiagnosed, thus clinicians 
should keep a low suspicion index. As autoimmune encephalopathies become more 
widely recognized, additional autoantibodies, features and atypical presentations are likely 
to be identified, as well as their real prevalence. The prevalence of autoimmunity in 
psychiatric disorders such as schizophrenia is the object of current research (103, 109), 
but its true contribution is yet to be accessed, and a role for immunotherapy is yet to be 
determined in these conditions. Also, further exploration is needed in order to accurately 
assess the epidemiology of autoimmune encephalitis, the clinical course of its various 
subgroups, and also to determine the most effective management strategies during acute 
illness and after discharge. 
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Antibody Patient 
Features 
Associated 
malignancies 
Common psychiatric 
symptoms Other findings 
Hu 
Older 
patients 
Smoking 
history 
SCLC 
Depression 
Hallucinatory activity 
Sleep disturbances 
Anxiety disorders 
Seizures 
Ataxia 
Consciousness 
impairment 
Painful sensitive 
neuropathy 
Gastrointestinal motility 
disorders 
Ma2 
Young 
males 
Older 
women 
Testicular 
germ cell 
tumor 
SCLC 
Sleep disturbances 
Anxiety disorders 
OCB 
Mood disturbances 
Supranuclear gaze palsy 
Cranial neuropathy 
Parkinsonism  
Hypothalamic dysfunction 
CV2/ 
CRMP5 
 
SCLC 
Thymoma 
Uterine 
sarcoma 
OCB 
Personality changes 
Mood disturbances 
Psychosis 
Subacute dementia 
Chorea 
Ocular disturbances 
(uveitis, optic neuritis) 
Olfactory/ taste loss 
Cerebellar ataxia 
Peripheral neuropathy 
Hu-AB can coexist 
Ri 
Older 
women 
Smoking 
history 
Lung cancer 
Breast cancer 
Cervical 
cancer 
Bladder 
cancer 
Behavioral changes 
Ataxia 
Opsoclonus-myoclonus 
Laryngospam 
Jaw-opening dystonia 
Visual blurring 
 
TABLE 1- Clinical features of the different oncoantibody associated disorders. 
Abbreviations: AB: Antibodies; CV2/CRMP5: Crossveinless-2/collapsing response 
mediated protein 5; OCB: Obsessive-compulsive behavior; SCLC: Small cell lung cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Patient 
Features 
Associated 
malignancies 
Common 
psychiatric 
symptoms 
Other findings 
LGI1 
Middle age to 
older patients 
males   
Personal/ 
familiar history 
of 
autoimmune 
disordersa   
Rare 
Behavioral 
changes 
Depression 
Delusions 
Hallucinations 
REM sleep 
disorders 
Hyponatremia 
FBDS 
Seizures 
Autonomic instability  
Neuromyotonia  
Ataxia 
Intestinal pseudo-
obstruction 
Caspr2 
Older males 
Personal/ 
familiar history 
of 
autoimmune 
disordersa   
Thymoma 
SCLC 
Severe insomnia 
Hallucination 
Personality 
changes  
Delusion 
Autonomic dysfunction  
Weight loss 
Neuromyotonia  
Painful neuropathy  
Seizures 
NMDAR 
Younger 
patients and 
children  
Paraneoplasti
c cases more 
common in 
non-caucasian 
females 
Ovarian 
teratoma 
SCLC 
Neuroblastoma 
Breast 
carcinoma 
Thymoma 
Delusion and 
hallucination 
Anxiety 
disorders 
Agression and 
agitation 
Bizarre behavior 
Mood disorders 
Prodromal flu-like  
Dissociative anesthesia 
Decreased conscience 
Seizures 
Autonomic instability 
Orofacial dyskinesia, facial 
grimacing, jaw opening 
distonia 
Opisthotonus, catatonic 
postures 
AMPAR Older females 
Breast cancer 
Lung carcinoma 
Thymoma 
Behavioral 
changes 
Sleep disorders  
Confabulation  
Hallucination 
Short-term memory 
impairment 
Seizures  
Confusion  
Relapsing disease  
GABAB 
Older men  
Younger 
nonparaneopl
astic group 
SCLC 
Thymoma 
Psychosis 
Hallucination 
Sleep 
disturbances 
 Paranoia 
Short-term memory 
impairment  
Seizures at presentation 
 
TABLE 2- Clinical features of the most common anti-surface autoimmune encephalitis. 
Abbreviations: AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; 
Caspr2: contactin-associated protein relates 2; FBDS: Fachiobraquial dystonic seizures; 
GABABR: Gamma-aminobutyric acid receptor; LG1: Leucine-rich glioma inactivated 1; 
NMDAR: N-methyl-D-aspartate receptor;SCLC: Small cell lung cancer; VGKC: Voltage-
gated potassium channel. a Data relates to anti-VGKC-complex-associated encephalitis. 
 
 
 
 
 
 
Paraneoplastic encephalitis 
Non-paraneoplastic autoimmune 
encephalitis 
Viral encephalitis  
Dementia, including neurodegenerative 
diseases (e.g. Alzheimer disease, 
Frontotemporal dementia) 
Malignancy (glioma, lymphoma) 
Temporal lobe seizures  
Wilson’s Disease 
Huntington’s disease 
Endocrine dysfunction (Hypothyroidism) 
Toxic-metabolic encephalopathy (e.g. 
sepsis, liver failure) 
Vitamin deficiency (Wernicke-Korsakoff 
encephalopathy, B12 or folic acid 
deficiency) 
Autoimmune systemic disorder (Lupus 
erythematosus, Vasculitis, Sjögren’s 
syndrome) 
Neurosyphilis 
Creuzfeldt-Jakob disease 
Primary psychiatric disorder 
 
TABLE 3 - Differential diagnosis of suspected autoimmune encephalopathies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent flu-like syndrome 
No past psychiatric illness 
Rapid onset of psychosis and/or catatonia  
Seizures/neurological dysfunction  
Known history of malignancy, especially if SCLC, teratoma or thymus cancer   
Signs of autonomic dysfunction  
Worsening of symptoms after antipsychotic ministration  
Refractory hyponatremia 
Long history of smoking 
Personal/family history of auto-immune disease 
 
TABLE 4 - features that should raise the suspicion of autoimmune etiology in case of 
atypical psychiatric presentation, particularly in first episode psychosis or mania. 
Abbreviation: ECT: electroconvulsive therapy; SCLC: Small cell lung cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody EEG changes MRI CSF 
abnormalities 
Prognosis 
Onco-AB Common, non 
specific 
Temporomesial 
hyperintensities 
Ma2: lesions 
outside the limbic 
system are 
common 
Common 
ymphocitic 
pleocytosis 
Mild elevation 
of protein levels 
Hu: Poor, median 
survival 12 months 
Ma2: 50-70% clinical 
stabilization/ 
improvement 
CV2/ CRMP5: poor, 
median survival 48 
months; 18 months if 
anti-HU antibodies 
coexist 
Ri: good response to 
treatment; better than 
CV2 or Hu 
LGI1 Common, non 
specific 
Temporomesial 
hyperintensities 
Cortical atrophy  
Mesiotemporal 
and basal ganglia 
hypermetabolism 
Rare 
Slight increase 
in proteins level 
Seldom OCB 
Excellent response to 
immunotherapy 
Improvement: 80%  
Full recovery: 24%  
Mortality: 6% 
Caspr2 Common, non 
specific Same as LGI1 Same as LGI1 
Poor prognosis, 
although good response 
to therapy 
NMDAR 
Common, non 
specific 
“Extreme 
delta brush” 
pattern 
Rare  
Abnormalities 
outside the medial 
temporal lobe 
Fronto-temporo-
parietal grandient 
on PET 
Very common 
Mild 
pleocytosis 
Raised protein 
level 
Oligoclonal 
bands  
Good 
Full recovery: 70-80% 
Mortality: 10% 
AMPAR Common, non 
specific 
Temporomesial 
hyperintensities 
Lesions outside 
the limbic system 
(i.e.,anterior septal 
nuclei, 
cerebellum) 
Common 
Lymphocitic 
pleyocitosis 
Poor, although good 
response to therapy 
Relapses are common 
GABABR Common, non specific 
Common 
Lymphocytic 
pleocytosis 
Abnormal in 
half of the 
cases 
Poor 
Full recovery: 18% 
Partial response: 36% 
 
Table 5 - Correlation between associated antibody frequency of findings in auxiliary 
exams and prognosis. Abbreviations: AMPAR: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; Caspr2: contactin-associated protein relates 2; 
CV2/CRMP5: crossveinless-2/collapsing response mediated protein 5; GABABR: Gamma-
aminobutyric acid receptor; LG1: Leucine-rich glioma inactivated 1; NMDAR: N-methyl-D-
aspartate receptor; PET: positron emission tomography; OCB: oligoclonal bands; VGKC: 
voltage-gated potassium channel 
 
Suspected malignancy Auxiliary exams 
SCLC Chest CT; if negative FDG-PET 
Non-SCLC Chest CT; if negative FDG-PET 
Thymoma Chest CT 
Testicular cancer Ultrasonography; if negative pelvic CT 
Teratoma Pelvic ultrasonography; if negative CT/MRI of 
pelvis/abdomen; if negative chest CT 
Breast cancer Mammography; if negative MRI; if negative FDG-PET 
 
TABLE 6 - Recommended auxiliary exams according suspected underlying malignancy. 
Abbreviations: CT: computed tomography; FDG-PET: fluorodeoxyglucose positron 
emission tomography; MRI: magnetic resonance imaging; SCLC: small cell lung cancer 
Figure 1 - Algorithm for antibody testing in autoimmune encephalopathies. Abbreviations: AMPAR: α-amino-3-hydroxy-5-meth-
yl-4-isoxazolepropionic acid receptor CV2/CRMP5: crossveinless-2/collapsing response mediated protein 5; GABABR: Gam¬-
ma-aminobutyric acid receptor; GAD: Glutamic Acid Descarboxylase; NMDAR: N-methyl-D-aspartate receptor; VGKC: Voltage-gat-
ed potassium channel. * Hypothalamic dysfunction includes diurnal hypersomnia, cataplexy, hyperphagia, hormonal deficits, 
hyperthermia, weight gain, and sexual dysfunction
AGRADECIMENTOS 
 
Devo um especial agradecimento ao Dr. João Massano pela orientação durante 
todo o processo que culminou com a elaboração deste projeto. Agradeço a 
disponibilidade, a amabilidade, a paciência, os conselhos e o conhecimento 
transmitido, sem os quais a abordagem de um tema já de si desafiante ter-se-ia 
tornado num trabalho muito mais complicado.  
Queria também agradecer ao Professor Rui Coelho pela disponibilidade e pelo 
aconselhamento.  
A todos os meus colegas de curso, que tornaram este percurso uma aventura 
única, dentro e fora das portas da faculdade, cujo peso que tiveram nestes seis 
anos não consigo sequer quantificar. 
A todos os docentes, médicos e não-médicos, que me ajudaram a construir as 
bases do conhecimento médico, e que me ajudaram na minha evolução 
profissional e pessoal.  
Por último, um especial agradecimento à minha família, pelo apoio 
incondicional e pela paciência que sempre demonstraram, sem os quais este 
projeto, a finalização deste mestrado ou a minha formação como pessoa e 
futura médica nunca teriam sido possíveis.  
 
  
 
 
 
 
 
 
 
 
 
 
 
ANEXOS 
Instructions for Authors
1
INSTRUCTIONS FOR AUTHORS
1. Aims and Scope
The International Journal of Clinical Neurosciences and Mental Health is an open-access 
peer-reviewed journal published trimonthly by ARC Publishing. 
Our goal is to provide high-quality publications in the areas of Psychiatry and Mental Health, 
Neurology, Neurosurgery and Medical Psychology. Expert leaders in these medical areas 
constitute the international editorial board. 
The journal publishes original research articles, review articles, drug reviews, case reports, 
case snippets, viewpoints, letters to the editor, editorials and guest editorials. 
The International Journal of Clinical Neurosciences and Mental Health follows the highest 
scientific standards, such as the CONSORT / STROBE guidelines and the Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals (ICJME).
The journal offers:
• Trusted peer review process
• Fast submission-to-publication time
• Open-access publication without author fees
• Multidisciplinary audience and global exposure
Contents
1. AIMS AND SCOPE 1
2. TYPES OF PAPERS 2
2.1. Original research articles 2
2.2. review articles and drug reviews 2
2.3. case repOrts and case snippets 2
2.4. viewpOints 3
2.5. letters tO the editOr 3
2.6. editOrials and guest editOrials 3
3. MANUSCRIPT SUBMISSION 3
3.1. cOver letter 3
3.2. Manuscript preparatiOn 3
3.3. suppOrting infOrMatiOn 5
3.4. subMissiOn checklist 6
4. OVERVIEW OF THE EDITORIAL PROCESS 6
4.1. appeal prOcess 6
Instructions for Authors
2
2. Types of papers
The International Journal of Clinical Neuroscience and Mental Health publishes scientific 
articles in the following categories:
• Original research articles. 
• Reviews.
• Drug reviews.
• Case reports.
• Case snippets.
• Viewpoints.
• Letters to the editor.
• Editorials and guest editorials.
2.1. Original research articles
The International Journal of Clinical Neurosciences and Mental Health welcomes original 
clinical research related with psychiatry, mental health, medical psychology, neurosurgery and 
neurology. 
Reports of randomized clinical trials should follow the CONSORT Guidelines and reports of 
observational studies should comply with STROBE Guidelines. 
Body text of an Original Research Article should have no more than 4000 words (word 
count excludes title page, abstract, acknowledgments, references and tables). A maximum of 6 
illustrations (figures or tables) are allowed. Supplementary online material may be submitted at 
the editor discretion.
2.2. Review articles and Drug Reviews
Review articles on CNS-related drugs, psychiatry, mental health, medical psychology, 
neurosurgery and neurology topics are welcome. Both invited and unsolicited submissions are 
accepted.
Manuscripts should be limited to a maximum of 4,500 words, excluding title page, abstract, 
acknowledgments, references and tables. 
2.3. Case reports and case snippets
Case Reports and Case Snippets should have no more than 750 and 500 words, respectively 
(word count excludes references); one figure or table can be included. 
Only highly meaningful Case Reports are accepted, including major educational content or 
major clinical findings. Case Snippets should describe a diagnosis or therapeutic challenge.
2.4. Viewpoints
Viewpoints should provide an expert opinion on important topics for medical research or 
practice, with possibility for covering social and policy aspects. This section encourages dialogue 
and debate on relevant issues with expert views based on evidence.
Viewpoints are limited to 1500 words (word count excludes references) and can include one 
figure or table.
Instructions for Authors
3
2.5. Letters to the Editor
Letters to the Editor should share views on published articles, any findings insufficient for a 
research article or present ideas of any subject in the scope of the journal.
Letters to the Editor have a maximum of 600 words (including references) and can include 
one figure or table.
2.6. Editorials and Guest Editorials
Authors are invited by the Editor-in-Chief to comment on specific topics and express their 
opinions. Editorials and Guest Editorials have a maximum of 1,000 words and can include one 
figure or table.
3. Manuscript Submission
These instructions advise on how the manuscript should be prepared and submitted. 
Manuscripts that do not comply with the guidelines will not be considered for review.
All manuscripts should be prepared in A4-size or US-letter size, in UK or US English. 
Manuscripts should be submitted in *.doc and *.pdf formats, in the appropriate section of the 
journal website: IJCNMH online submission.
3.1. Cover Letter
A cover letter should be submitted together with the manuscript, in *.doc or *.pdf format, 
addressed to the Editor-in-Chief. 
A template for the cover letter is available for download.
The cover letter should contain statements about originality of your publication, Ethics 
Committee approval and informed consent (if applicable), conflicts of interest and why in your 
opinion your manuscript should be published.
3.2. Manuscript Preparation
The manuscript must be divided in 2 files: the Title page (submitted in *.doc format and *.pdf 
formats) and the Manuscript body (submitted in *.doc and *.pdf formats). 
Title page
This should be submitted as a separate file from your manuscript (to assure anonymity in the 
peer review process) and should include:  
• Article title.
• Authors’ names, titles (e.g. MD, PhD, MSc, etc.) and institutional affiliations.
• Corresponding author: name, mailing address, telephone and fax numbers.
• Keywords (maximum of 10).
• A running head (up to 50 characters).
• Abstract word count (up to 250 words).
• Body text word count. 
• The number of figures and tables.
Instructions for Authors
4
Manuscript body:
The Manuscript body must be anonymous, not containing the names or affiliations of the 
authors. Manuscript body must be structured in the following order: title, abstract, body text, 
acknowledgements, references, tables, and figures captions/legends.
• The text must be formatted as follow:
• Arial fonts, size: 11 points.
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• Aligned to the left (not justified). 
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line numbers by going to: Page Layout -> Line Numbers -> select “Continuous”; for OpenOffice:  
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A descriptive and scientifically accurate article title should be provided.
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An abstract should be prepared for Original Research Articles, Review Articles and Drug 
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conclusions. These sections should be separated by the respective headings. 
If the publication is associated with a registered clinical trial, the trial registration number 
should be referred at the end of the abstract.
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Original research articles
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Introduction: Should present the background for the investigation and justify its relevancy. 
Claims should be supported by appropriate references. Introduction should end by stating 
the objectives of the study.
Methods: Should allow the reproduction of results and therefore must provide enough 
detail. Appropriate subheadings can be included, if needed.
Results: Should include detailed descriptions of generated data. This section can be 
separated into subsections with concise self-explanatory subheadings.
Discussion and Conclusions: Should be brief but comprehensive and well argued, 
summarise and discuss the main findings, their clinical relevance, the strengths and 
limitations of the study, future perspectives with suggestion of experiments to be addressed 
in the future.
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Medical Association (Declaration of Helsinki). Authors should provide information regarding 
ethics on research participants, patient informed consent, data privacy as well as competing 
interests. If the authors have submitted a related manuscript elsewhere should disclose this 
information prior submission. 
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All units should be in International System (SI). Drugs should be designated by their 
International Non-Proprietary Name (INN).
3.4. Submission Checklist
Please ensure you have addressed the following issues prior submission:
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is based on technical and scientific merits of the work. Reviewers can be asked to be disclosed 
or stay anonymous. Authors can exclude specific editors or reviewers from the process, upon 
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the manuscript enters the production process. It takes approximately 6-7 weeks for the 
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